111 related articles for article (PubMed ID: 37504965)
1. Formulation of Recombinant H1N1 Hemagglutinin in MF59 and Alum Adjuvants: A Comparison of the Vaccines Potency and Efficacy in BALB/C Mice.
Sepasi A; Ghafourian M; Taghizadeh M; Mahdavi M
Viral Immunol; 2023; 36(6):401-408. PubMed ID: 37504965
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Immune Response of Recombinant H1N1 Hemagglutinin with MF59 Adjuvant in Animal Model as a Novel Alternative to the Influenza Vaccine.
Rashedi N; Taghizadeh M; Mohamadynejad P; Mahdavi M; Jalalirad R
Iran J Allergy Asthma Immunol; 2020 Oct; 19(5):497-508. PubMed ID: 33463117
[TBL] [Abstract][Full Text] [Related]
3. Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses.
Haghighi M; Khorasani A; Karimi P; Keshavarz R; Mahdavi M
Viral Immunol; 2022 Dec; 35(10):663-672. PubMed ID: 36534465
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory Effects of
Eshraghi Y; Vahdani Y; Karimi P; Abdollahpour-Alitappeh M; Abdoli A; Taghizadeh M; Mahdavi M
Viral Immunol; 2022 Apr; 35(3):244-253. PubMed ID: 35467429
[TBL] [Abstract][Full Text] [Related]
5. Nanocurcumin as an adjuvant in killed Toxoplasma gondii vaccine formulation: An experience in BALB/c mice.
Mahdi Ghahari SM; Ajami A; Sadeghizadeh M; Esmaeili Rastaghi AR; Mahdavi M
Exp Parasitol; 2022 Dec; 243():108404. PubMed ID: 36265591
[TBL] [Abstract][Full Text] [Related]
6. Cross-protective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus.
Yang S; Niu S; Guo Z; Yuan Y; Xue K; Liu S; Jin H
Virol J; 2013 Sep; 10():291. PubMed ID: 24053449
[TBL] [Abstract][Full Text] [Related]
7. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.
Valensi JP; Carlson JR; Van Nest GA
J Immunol; 1994 Nov; 153(9):4029-39. PubMed ID: 7930610
[TBL] [Abstract][Full Text] [Related]
8. Formulation of a recombinant HIV-1 polytope candidate vaccine with naloxone/alum mixture: induction of multi-cytokine responses with a higher regulatory mechanism.
Fathi M; Nezamzadeh R; Abdollahpour-Alitappeh M; Yazdi MH; Khoramabadi N; Mahdavi M
APMIS; 2021 Aug; 129(8):480-488. PubMed ID: 33539574
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice.
Ou H; Yao H; Yao W; Wu N; Wu X; Han C; Cheng L; Chen K; Chen H; Li L
Vaccine; 2016 Apr; 34(20):2362-70. PubMed ID: 27013436
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
11. PPD in HBsAg vaccine formulation suppressed IFN-γ and IL-4 cytokine responses and induced long-lived humoral immune responses: Results from 220-day monitoring of specific IgG responses.
Mirzaee R; Nemati F; Mirzaee M; Golkaran B; Khorasani A; Rashedi N; Asgarhalvaei F; Savoji MA; Mahdavi M
Iran J Basic Med Sci; 2022 Nov; 25(11):1326-1333. PubMed ID: 36474577
[TBL] [Abstract][Full Text] [Related]
12. Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants.
He L; Sun B; Guo Y; Yan K; Liu D; Zang Y; Jiang C; Zhang Y; Kong W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108216. PubMed ID: 34634689
[TBL] [Abstract][Full Text] [Related]
13. Montanide ISA-720 and Naloxone in HBsAg Vaccine Formulation: Cytokine Profiling and Monitoring of Long-Lasting Humoral Immune Responses.
Mirzaee M; Haghighat S; Golkaran B; Asgarhalvaei F; Mirzaee R; Taghizadeh M; Savoji MA; Esfandiari B; Mahdavi M
Biomed Environ Sci; 2022 Sep; 35(9):792-803. PubMed ID: 36189994
[TBL] [Abstract][Full Text] [Related]
14. Poly(I:C)/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting.
Chuai X; Chen H; Wang W; Deng Y; Wen B; Ruan L; Tan W
PLoS One; 2013; 8(1):e54126. PubMed ID: 23335993
[TBL] [Abstract][Full Text] [Related]
15. Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection against Heterologous Influenza A Viruses.
Kwak C; Nguyen QT; Kim J; Kim TH; Poo H
J Microbiol Biotechnol; 2021 Feb; 31(2):304-316. PubMed ID: 33263336
[TBL] [Abstract][Full Text] [Related]
16. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action.
Caproni E; Tritto E; Cortese M; Muzzi A; Mosca F; Monaci E; Baudner B; Seubert A; De Gregorio E
J Immunol; 2012 Apr; 188(7):3088-98. PubMed ID: 22351935
[TBL] [Abstract][Full Text] [Related]
17. Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.
Yam KK; Gupta J; Allen EK; Burt KR; Beaulieu É; Mallett CP; Burt DS; Ward BJ
Vaccine; 2016 Mar; 34(12):1444-51. PubMed ID: 26873056
[TBL] [Abstract][Full Text] [Related]
18. Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB/c mice against influenza A/PR8/H1N1 virus challenge.
Forqani M; Hosseini SM; Farahmand B; Saleh M; Shokouhi H; Torabi A; Fotouhi F
Biotechnol Lett; 2021 Nov; 43(11):2137-2147. PubMed ID: 34491470
[TBL] [Abstract][Full Text] [Related]
19. Truncated Core/NS3 Fusion Protein of HCV Adjuvanted with Outer Membrane Vesicles of Neisseria meningitidis Serogroup B: Potent Inducer of the Murine Immune System.
Hekmat S; Sadat SM; Aslani MM; Mahdavi M; Bolhassani A; Asgar Halvaee F; Ghahari SMM; Aghasadeghi MR; Siadat SD
Iran Biomed J; 2019 Jul; 23(4):235-45. PubMed ID: 30278608
[TBL] [Abstract][Full Text] [Related]
20. Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.
Velashjerdi Farahani S; Reza Aghasadeghi M; Memarnejadian A; Faezi S; Shahosseini Z; Mahdavi M
Pathog Glob Health; 2016 Mar; 110(2):39-47. PubMed ID: 26403975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
